Key Takeaways:
British drugmaker GSK’s experimental cancer therapy Mo-rez has blockbuster potential of more than $1 billion in annual sales, the company said after early data showed the drug helped shrink tumors in advanced-stage patients.
"The data shows Mo-rez has blockbuster potential," GSK's head of oncology research told reporters on April 12.
The early-stage trial data indicated that the targeted therapy was effective in shrinking tumors for patients with a range of advanced, hard-to-treat cancers. While specific efficacy and safety data points were not yet disclosed, the qualitative results were strong enough for the company to highlight the drug's significant commercial prospects. Mo-rez is a key asset in the company's oncology pipeline.
For GSK, the positive data provides a much-needed boost to its research and development pipeline and could lead to a significant rally in its stock price. A blockbuster drug would substantially increase future revenue and profitability, validating the company's strategic focus on targeted oncology treatments.
The results suggest GSK's investment in its oncology pipeline is beginning to yield high-value candidates. Investors will now watch for the full data presentation at an upcoming medical conference and the announcement of the timeline for a pivotal Phase 3 trial.
This article is for informational purposes only and does not constitute investment advice.
